New pill could ease heavy periods from fibroids
NCT ID NCT07402369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called CMS-D002 for women with uterine fibroids who have heavy menstrual bleeding. About 120 women aged 18-50 will take either the drug or a placebo daily for 12 weeks. The goal is to see if the drug can reduce bleeding to normal levels and shrink fibroids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CMS-D002 capsule
- What this could lead to
- If successful, this could offer a new non-surgical option to reduce heavy bleeding and improve quality of life for women with uterine fibroids.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE FIBROIDS WITH MENORRHAGIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China